Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPD | P32754 | 3/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.44 |
| ▸ | PRKDC | P78527 | 8/20 | 0.44 |
| ▸ | MTOR | P42345 | 4/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5836181 | 0.81 | HPD (0.53) | HPDHSD11B1PIK3CAPRKDCMTOR | |
| SCHEMBL6208794 | 0.79 | HPD (0.56) | HPDHSD11B1PIK3CAPRKDCMTOR | |
| SCHEMBL5836240 | 0.78 | ALDH1A1 (0.58) | HSD11B1DRD2SLC6A4SMN1; SMN2KDM4E | |
| SCHEMBL5836092 | 0.77 | HPD (0.50) | HPDHSD11B1PIK3CAPRKDCMTOR | |
| SCHEMBL6054650 | 0.76 | HPD (0.48) | HPDSMN1; SMN2KDM4EBRD4ALDH1A1 | |
| SCHEMBL989522 | 0.75 | L3MBTL1 (0.41) | KDM4EALDH1A1 | |
| SCHEMBL5838497 | 0.74 | HPD (0.44) | HPDHSD11B1PIK3CAPRKDCMTOR | |
| SCHEMBL5836712 | 0.73 | HPD (0.50) | HPDHSD11B1PIK3CAPRKDCMTOR | |
| SCHEMBL3605908 | 0.72 | HTR1A (0.44) | SMN1; SMN2KDM4EBRD4ALDH1A1 | |
| SCHEMBL5836717 | 0.69 | HPD (0.48) | HPDHSD11B1PIK3CAPRKDCMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056918-B2 | Benzimidazole anti-inflammatory compounds | PFIZER, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1370557-B1 | BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS | PFIZER PROD INC (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1370557-A1 | BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS | Pfizer Products Inc. (US) | 2003-12-17 | — | — | EP | disclosed |
| US-20030092749-A1 | Novel benzimidazole anti-inflammatory compounds | PFIZER INC. | 2003-05-15 | — | — | US | disclosed |
| WO-2002072576-A1 | BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092749-A1 | Novel benzimidazole anti-inflammatory compounds | MAPK1, JAK1, CNKSR1 | HPD 4598/4885HSD11B1 3213/4885PIK3CA 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.